Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3432MR)

This product GTTS-WQ3432MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3432MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9999MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ15502MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12908MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ9734MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ6222MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ14409MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13754MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ6084MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW